Martin R Gaudinski, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
7
6
6
N/A
0
2
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+2 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Michael C Sneller, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Shared therapeutic areas:
Worked with same sponsors:
Craig Hendrix, MD
Johns Hopkins University
Shared therapeutic areas:
Worked with same sponsors:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Pablo Tebas, MD
University of Pennsylvania
Shared therapeutic areas:
Worked with same sponsors:
Neha sharma, PhD
Warwick Research Services
Shared therapeutic areas:
Steven Grinspoon, MD
Massachusetts General Hospital
Shared therapeutic areas:
Katie Mollan, PhD
University of North Carolina, Chapel Hill
Shared therapeutic areas:
Michael Hudgens, PhD
University of North Carolina, Chapel Hill
Shared therapeutic areas:
Gates MRI
Gates Medical Research Institute
Shared therapeutic areas:
Robert Yarchoan, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
All 7 trials loaded